查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445545

全球糖尿病视网膜病变市场评估：按疾病类型、治疗、最终用户和地区划分的机会和预测（2017-2031）

Diabetic Retinopathy Market Assessment, By Disease Form, By Treatment, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 234 Pages | 商品交期: 3-5个工作天内

价格

全球糖尿病视网膜病变市场规模将从 2023 年的 90.3 亿美元增至 2031 年的 146.8 亿美元，2024-2031 年预测期间复合年增长率为 6.26%，预计将会增长。

全球糖尿病视网膜病变市场受到多种因素的推动，例如糖尿病盛行率增加、技术进步、糖尿病相关疾病数量增加、非增殖性糖尿病视网膜病变需求增加以及抗 VEGF 药物日益普及。因素。 尖端技术进步，特别是人工智慧的整合，在影响全球糖尿病视网膜病变市场方面发挥关键作用。 人工智慧透过分析大量复杂数据来寻找糖尿病视网膜病变的模式，在提高诊断速度和准确性方面发挥重要作用。 上市公司和私人公司正大力投资糖尿病视网膜病变相关技术。 这些投资用于研发目的并帮助开发先进的解决方案。 在许多情况下，上市公司和私人公司正在利用彼此的优势来推动全球糖尿病视网膜病变市场的创新，并为市场不断增长的需求做出贡献。

影响全球糖尿病视网膜病变市场的另一个重要面向是糖尿病盛行率的增加。 糖尿病视网膜病变发生在早期发现糖尿病或未接受适当治疗的患者。 对于在疾病早期阶段治疗非增殖性 DR 的药物的需求不断增长，因为早期治疗是预防疾病进展的关键。 对于糖尿病视网膜病变的治疗，优选非侵入性治疗，例如药物治疗。 这些药物已被证明对糖尿病视网膜病变非常有效。 主要参与者正在进行临床试验，从而发现有效的创新药物。

技术进步

全球糖尿病视网膜病变市场的成长受到技术进步的显着影响，尤其是与人工智慧相关的技术进步。 人工智慧的整合提高了糖尿病视网膜病变的检测效率和准确性。 透过人工智慧演算法，医生可以高精度地早期预测患者患糖尿病视网膜病变的可能性。 这种能力对于早期预后以及提供可能挽救生命的及时干预措施至关重要。

主要参与者的大量投资

另一个重要的市场趋势是各医疗器材公司为推动全球糖尿病视网膜病变市场的创新和技术进步而进行的大量投资。 需要获得此类资金来製定检测糖尿病视网膜病变的新策略和加强研发计划的技术。 製药公司正在研发上投入大量资金，以创造糖尿病视网膜病变的新疗法。 此外，製药公司、学术机构和医疗保健组织之间的合作正在支持尖端糖尿病视网膜病变治疗的开发。 在糖尿病视网膜病变的治疗中，多种药物和治疗方法相结合的联合疗法正在变得流行。

本报告调查了全球糖尿病视网膜病变市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。我们编制分析、案例研究、竞争格局、主要公司简介等等。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球糖尿病视网膜病变市场展望

  • 市场规模/预测
  • 依疾病类型
    • 增殖性糖尿病视网膜病变
    • 非增殖性糖尿病视网膜病变
  • 透过治疗
    • 雷射手术
    • 眼内类固醇注射
    • 玻璃体手术
    • 抗 VEGF 剂
    • 其他
  • 按最终用户
    • 医院
    • 眼科中心
    • 门诊手术中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第 5 章全球糖尿病视网膜病变市场展望：按地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 依疾病类型
  • 依治疗方法
  • 按最终用户
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 生长抑制因素（问题、限制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Alimera Sciences, Inc
  • AbbVie Inc
  • Regeneron Pharmaceuticals Inc
  • Ampio Pharmaceuticals, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Sirnaomics Ltd
  • Kowa Co Ltd
  • Ocuphire Pharma, Inc.
  • Oxurion NV

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX11094

The global diabetic retinopathy market is projected to witness a CAGR of 6.26% during the forecast period 2024-2031, growing from USD 9.03 billion in 2023 to USD 14.68 billion in 2031. The global diabetic retinopathy market is being driven by various factors, such as the increasing prevalence of diabetes, technological advancements, an increasing number of diabetes related disorders, growing demand for non-proliferative diabetic retinopathy, and increasing popularity of anti-VEGF medications. Advancements in cutting-edge technologies, especially the integration of artificial intelligence, play an important role in influencing the global diabetic retinopathy market. AI is responsible for improving the speed and accuracy of diagnosis by analyzing large amounts of complex data for patterns that indicate diabetic retinopathy. Both public and private firms are investing significantly in diabetic retinopathy related technologies. These investments are used for R&D purposes, which help in developing advanced solutions for the market. Often, public and private firms utilize each other's strengths to spur innovation in the global diabetic retinopathy market, which, in turn, helps expand the market demand.

Another important aspect influencing the global diabetic retinopathy market is the increasing prevalence of diabetes. Diabetic retinopathy is found in patients, where diabetes is not detected in the early stages or the patients who don't receive proper treatment. Early care is key to preventing the disease's progression, so there is a greater demand for medications for non-proliferative DR which is an early stage of the disease. Patients prefer non-invasive forms of treatment for treating diabetic retinopathy, such as medications. These medications have proven to be highly effective in combatting the disease. Major market players are conducting clinical trials, which leads to the discovery of effective and innovative drugs.

In November 2023, Exonate Ltd, a mRNA therapy company involved in creating solutions for the treatment of diabetic complications, announced the successful completion of a clinical trial for EXN407, its lead asset for ophthalmology. EXN407 is the first topical treatment for diabetic macular edema and diabetic retinopathy.

Technological Advancements

The expansion of the global diabetic retinopathy market is being significantly affected by advancing technologies, specifically related to AI. The integration of AI improves the detection efficiency and accuracy of diabetic retinopathy by using advanced diagnosis tools. Through AI algorithms, physicians can predict the chances of a patient developing diabetic retinopathy earlier with high accuracy. This capability is crucial for early prognosis since it makes timely interventions that might save lives. As a result, AI is causing a revolution in the field of diabetic retinopathy, improving outcomes and accelerating the expansion of the enterprise. Also, the use of injectable medications and laser technologies helps diabetic retinopathy effectively. In April 2023, Sankara Nethralaya, an eye hospital based in Chennai, India, announced its partnership with RetinaRisk, a health tech company from Iceland, to adopt a mathematical tool to predict the chances of a person developing diabetic retinopathy.

Significant Investments by Key Market Players

Another significant market trend includes significant investments by various medical device companies to drive innovation and technological advancements in the global diabetic retinopathy market. This access to funding is necessary to enable the development of new strategies for the detection of diabetic retinopathy and technologies to enhance research and development initiatives. To create new treatments for diabetic retinopathy, pharmaceutical companies are heavily funding research and development. Additionally, partnerships between pharmaceutical companies, academic institutions, and healthcare organizations are assisting in the development of cutting-edge diabetic retinopathy therapies. Combination therapies, which use several medications or therapeutic modalities, are becoming more and more popular in the management of diabetic retinopathy.

On 14th february 2024, the Advanced Research Projects Agency for Health (ARPA-H) granted funding of $20 million to a biomedical engineering professor in the McKelvey School of Engineering at Washington University. The contract is a component of ARPA-H's initial request for proposals, which aims to provide innovative methods for enhancing health outcomes for various patient populations, communities, diseases, and health conditions using ground-breaking research and cutting-edge technologies.

Increasing Demand for Non-Proliferative Diabetic Retinopathy Medications

The growing need for therapies that address the early stages of the illness, known as non-proliferative diabetic retinopathy (NPDR), is a major factor driving the growth of the global diabetic retinopathy market. The need for early detection and treatment of diabetic eye problems has increased due to the global rise in the prevalence of diabetes. The goal of NPDR treatments is to prevent or slow the disease's advancement to its more serious proliferative stages, which increases the risk of complete loss of vision. Increased awareness and use of advanced screening procedures have led to an earlier detection of the condition, thus surging the demand for these drugs. The global diabetic retinopathy market is being driven by this trend, which incentivizes pharmaceutical companies to heavily invest in the study to develop specialized treatments for NPDR.

OcuTerra Therapeutics, Inc., a clinical-stage ophthalmology company, announced in July 2023 that the clinical trial assessing OTT168 topical eye drops for adult patients with moderately severe to severe non-proliferative diabetic retinopathy has completed enrollment in the Phase 2 DR:EAM trial (Diabetic Retinopathy: Early Active Management).

Growing Popularity of Anti-VEGF Medications

The global diabetic retinopathy market is undergoing significant expansion due to the increasing demand for anti-VEGF medications to treat diabetic retinopathy. Anti-VEGF medications are used to treat early symptoms of diabetic retinopathy to prevent further vascular leakage, reduce inflammation, and prevent loss of vision. Anti-VEGF medications, such as aflibercept and ranibizumab, stop the abnormal blood vessels behind the retina from rupturing, expanding, and eventually bleeding. Vascular endothelial growth factor (VEGF) is a protein that causes aberrant blood vessels to form in the retina, and anti-VEGF works against this protein.

In April 2023, Ximluci, a ranibizumab biosimilar, was introduced in many European countries by STADA Arzneimittel, a pharmaceutical company, Xbrane Biopharma, based in Sweden.

North America Dominates the Market

North American countries possess a robust healthcare ecosystem that is concentrated with technologically advanced medical device and pharmaceutical companies. The region leads the global diabetic retinopathy market for a variety of reasons. The area has a higher-than-average incidence of diabetic retinopathy driven by the growing aging population and sedentary lifestyles. The public is also aware of diabetes and its complications, which promotes early detection and intervention. Furthermore, North America is known for its emphasis on research and development, along with advanced healthcare infrastructure and significant healthcare budgets, which makes it easier to obtain state-of-the-art diabetes treatments and diagnostics.

In April 2023, the LumineticsCore AI diagnostic system was launched by Digital Diagnostics, an AI-based diagnostic healthcare company, in the southeast region of the US. It is an FDA-approved device that helps in examining the retinal images of people suffering from diabetic retinopathy.

Future Market Scenario (2024 - 2031F)

The future of the global diabetic retinopathy market includes smart devices that will enable the diagnosis of diabetic retinopathy without the need for human intervention.

Globally, many children are being diagnosed with type-1 and type-2 diabetes, thus increasing the number of childhood hyperglycaemia cases, which are associated with an increased risk of developing diabetic retinopathy in the future.

The introduction of a new class of therapeutics called "Stress Resilience-Enhancing Drugs" (SREDs) is going to drive the global diabetic retinopathy market. Through phosphodiesterase inhibition, these medications protect the structure and function of the degenerating retina.

Biomarkers and OCTA (Optical Coherence Tomography Angiography) are being used extensively for assessing and monitoring diabetic retinopathy and diabetic macular edema. Biomarkers provide an in vivo assessment of the health of the retina and choroid non-invasively. OCTA, on the other hand, offers detailed information on the retinochoroidal microvasculature, including precise areas of capillary non-perfusion, presence of collaterals or retinal/optic nerve head neovascularization, and abnormalities of the foveal avascular zone.

Key Players Landscape and Outlook

To strengthen their position in the market and expedite the creation and dissemination of cutting-edge therapies, major players in the global diabetic retinopathy market are forming partnerships. Through partnerships, companies can broaden their geographic reach and penetrate new markets by capitalizing on the regulatory and local expertise of their partners. This cooperative strategy promotes competition, which can result in better patient outcomes and cost savings, in addition to advancing the development of more accessible and effective treatments for diabetic retinopathy.

In November 2023, Lupin Ltd, an Indian multinational pharmaceutical company, and Amman Pharma, one of the first pharmaceutical companies in the MENA region, entered a collaboration for the supply and licensing of Ranibizumab in the Middle East and North Africa region, including Iraq, Saudi Arabia, Jordan, the UAE, Lebanon and other GCC countries. It is a biosimilar drug used for the treatment of diabetic retinopathy.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Diabetic Retinopathy Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Disease Form
    • 4.2.1. Proliferative Diabetic Retinopathy
    • 4.2.2. Non-Proliferative Diabetic Retinopathy
  • 4.3. By Treatment
    • 4.3.1. Laser Surgery
    • 4.3.2. Intraocular Steroid Injection
    • 4.3.3. Vitrectomy
    • 4.3.4. Anti-VEGF
    • 4.3.5. Others
  • 4.4. By End-user
    • 4.4.1. Hospitals
    • 4.4.2. Ophthalmic Centers
    • 4.4.3. Ambulatory Surgical Centers
    • 4.4.4. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Diabetic Retinopathy Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Disease Form
      • 5.1.2.1. Proliferative Diabetic Retinopathy
      • 5.1.2.2. Non-Proliferative Diabetic Retinopathy
    • 5.1.3. By Treatment
      • 5.1.3.1. Laser Surgery
      • 5.1.3.2. Intraocular Steroid Injection
      • 5.1.3.3. Vitrectomy
      • 5.1.3.4. Anti-VEGF
      • 5.1.3.5. Others
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Ophthalmic Centers
      • 5.1.4.3. Ambulatory Surgical Centers
      • 5.1.4.4. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Disease Form
      • 5.1.5.2.1. Proliferative Diabetic Retinopathy
      • 5.1.5.2.2. Non-Proliferative Diabetic Retinopathy
      • 5.1.5.3. By Treatment
      • 5.1.5.3.1. Laser Surgery
      • 5.1.5.3.2. Intraocular Steroid Injection
      • 5.1.5.3.3. Vitrectomy
      • 5.1.5.3.4. Anti-VEGF
      • 5.1.5.3.5. Others
      • 5.1.5.4. By End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Ophthalmic Centers
      • 5.1.5.4.3. Ambulatory Surgical Centers
      • 5.1.5.4.4. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Disease Form
  • 6.2. By Treatment
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Alimera Sciences, Inc
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. AbbVie Inc
  • 13.3. Regeneron Pharmaceuticals Inc
  • 13.4. Ampio Pharmaceuticals, Inc.
  • 13.5. Bayer AG
  • 13.6. F. Hoffmann-La Roche Ltd.
  • 13.7. Sirnaomics Ltd
  • 13.8. Kowa Co Ltd
  • 13.9. Ocuphire Pharma, Inc.
  • 13.10. Oxurion NV

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 4. Global Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 5. Global Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Diabetic Retinopathy Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 10. North America Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 11. North America Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Diabetic Retinopathy Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 16. United States Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 17. United States Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 21. Canada Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 22. Canada Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 26. Mexico Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 27. Mexico Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 31. Europe Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 32. Europe Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Diabetic Retinopathy Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 37. Germany Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 38. Germany Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 42. France Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 43. France Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 47. Italy Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 48. Italy Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 52. United Kingdom Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 53. United Kingdom Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 57. Russia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 58. Russia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 62. Netherlands Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 63. Netherlands Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 67. Spain Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 68. Spain Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 72. Turkey Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 73. Turkey Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 77. Poland Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 78. Poland Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 82. South America Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 83. South America Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Diabetic Retinopathy Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 88. Brazil Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 89. Brazil Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 93. Argentina Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 94. Argentina Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 98. Asia-Pacific Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 99. Asia-Pacific Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Diabetic Retinopathy Market Share (%), By Country, 2017-2031F
  • Figure 101. India Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 104. India Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 105. India Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 109. China Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 110. China Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 114. Japan Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 115. Japan Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 119. Australia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 120. Australia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 124. Vietnam Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 125. Vietnam Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 129. South Korea Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 130. South Korea Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 134. Indonesia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 135. Indonesia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 139. Philippines Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 140. Philippines Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 144. Middle East & Africa Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 145. Middle East & Africa Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Diabetic Retinopathy Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 150. Saudi Arabia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 151. Saudi Arabia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 155. UAE Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 156. UAE Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F
  • Figure 160. South Africa Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F
  • Figure 161. South Africa Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Disease Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023